Kodiak Sciences

Kodiak's stock doubles with win for resurrected eye disease drug

Two of Kodiak's candidates matched aflibercept in a phase 3 trial, positioning the biotech to seek approval of one of the eye disease assets this year.

Nick Paul Taylor Sep 28, 2026 8:37am

Kodiak resurrects eye drug after ph. 3 data renew approval plans

Nov 6, 2023 8:40am

quit fire layoff workforce reduction exit

Kodiak's CMO hands in notice a month after pair of phase 3 fails

Aug 18, 2023 7:35am

'Unexpected' cataracts in ph. 3 end Kodiak's hopes for eye drug

Jul 24, 2023 8:58am

Kodiak asset matches Regeneron's Eylea in macular edema phase 3

Aug 8, 2022 9:53am

Kodiak's vision loss drug flops first of 6 phase 3 studies

Feb 23, 2022 10:00am